Sensitive detection of low-abundance proteins in complex biological samples has typically been achieved by immunoassays that use antibodies specific to target proteins; however, de novo development of antibodies is associated with high costs, long development lead times, and high failure rates. To address these challenges, we developed an antibody-free strategy that involves PRISM (high-pressure, high-resolution separations coupled with intelligent selection and multiplexing) for sensitive selected reaction monitoring (SRM)-based targeted protein quantification. The strategy capitalizes on high-resolution reversed-phase liquid chromatographic separations for analyte enrichment, intelligent selection of target fractions via on-line SRM monitoring of internal standards, and fraction multiplexing before nano-liquid chromatography-SRM quantification. Application of this strategy to human plasma/serum demonstrated accurate and reproducible quantification of proteins at concentrations in the 50-100 pg/mL range, which represents a major advance in the sensitivity of targeted protein quantification without the need for specific-affinity reagents. Application to a set of clinical serum samples illustrated an excellent correlation between the results obtained from the PRISM-SRM assay and those from clinical immunoassay for the prostate-specific antigen level.biomarker verification | systems biology | targeted proteomics S elected reaction monitoring (SRM), also known as multiple reaction monitoring (MRM), has recently emerged as a promising technology (1-16) for high-throughput mass spectrometry (MS)-based quantification of targeted proteins in biological and clinical specimens (e.g., tumor tissues). SRM has demonstrated relatively good selectivity, reproducibility (or precision), and sensitivity for a range of multiplexed protein assays (2, 4-8, 11, 17, 18) and has potential for quantifying protein isoforms (19) and posttranslational modifications (PTMs) (3,(20)(21)(22) for which good quality antibodies often do not exist. Nevertheless, a major limitation of current SRM technology is insufficient sensitivity for detecting low-abundance proteins present at sub-nanogram per milliliter levels in human blood plasma or serum and extremely low-abundance proteins in cells or tissues. Without sample prefractionation, liquid chromatography (LC)-SRM measurements have been limited to only moderately abundant proteins in human plasma present in the low microgram per milliliter range (2,6,8).More recently, the combination of immunoaffinity depletion and fractionation by strong cation exchange (SCX) chromatography (4, 23), along with advances in MS sensitivity (24), has extended SRM quantification of plasma proteins to low nanogram per milliliter levels (4, 23). SISCAPA (stable isotope standards and capture by anti-peptide antibodies) coupled with SRM demonstrated quantification of target proteins in the same range, using as little as 10 μL of human plasma (8,(25)(26)(27). SISCAPA assays have some distinct advantages over conventiona...

The separation of biologically active, pure, and specific tRNAs is difficult due to the overall similarity in secondary and tertiary structures of different tRNAs. Because prior methods do not facilitate high-resolution separations of the extremely complex mixture represented by a cellular tRNA population, global studies of tRNA identity and/or abundance are difficult. We have discovered that the enzymatic digestion of an individual tRNA by a ribonuclease (e.g., RNase T1) will generate digestion products unique to that particular tRNA, and we show that a comparison of an organism's complete complement of tRNA RNase digestion products yields a set of unique or ''signature'' digestion product(s) that ultimately enable the detection of individual tRNAs from a total tRNA pool. Detection is facilitated by matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) and proof-of-principle is demonstrated on the whole tRNA pool from Escherichia coli. This method will enable the individual identification of tRNA isoacceptors without requiring specific affinity purification or extensive chromatographic and/or electrophoretic purification. Further, experimental identifications of tRNAs or other RNAs will now be possible using this signature digestion product approach in a manner similar to peptide mass fingerprinting used in proteomics, allowing RNomic studies of RNA at the post-transcriptional level.

Interest in the application of advanced proteomics technologies to human blood plasma- or serum-based clinical samples for the purpose of discovering disease biomarkers continues to grow; however, the enormous dynamic range of protein concentrations in these types of samples (often >10 orders of magnitude) represents a significant analytical challenge, particularly for detecting low-abundance candidate biomarkers. In response, immunoaffinity separation methods for depleting multiple high- and moderate-abundance proteins have become key tools for enriching low-abundance proteins and enhancing detection of these proteins in plasma proteomics. Herein, we describe IgY14 and tandem IgY14-Supermix separation methods for removing 14 high-abundance and up to 60 moderate-abundance proteins, respectively, from human blood plasma and highlight their utility when combined with liquid chromatography-tandem mass spectrometry for interrogating the human plasma proteome.

Selected reaction monitoring mass spectrometry (SRM-MS) is playing an increasing role in quantitative proteomics and biomarker discovery studies as a method for high throughput candidate quantification and verification. Although SRM-MS offers advantages in sensitivity and quantification compared with other MS-based techniques, current SRM technologies are still challenged by detection and quantification of low abundance proteins (e.g. present at ϳ10 ng/ml or lower levels in blood plasma). Here we report enhanced detection sensitivity and reproducibility for SRM-based targeted proteomics by coupling a nanospray ionization multicapillary inlet/ dual electrodynamic ion funnel interface to a commercial triple quadrupole mass spectrometer. Because of the increased efficiency in ion transmission, significant enhancements in overall signal intensities and improved limits of detection were observed with the new interface compared with the original interface for SRM measurements of tryptic peptides from proteins spiked into nondepleted mouse plasma over a range of concentrations. Overall, average SRM peak intensities were increased by ϳ70-fold. The average level of detection for peptides also improved by ϳ10-fold with notably improved reproducibility of peptide measurements as indicated by the reduced coefficients of variance. The ability to detect proteins ranging from 40 to 80 ng/ml within mouse plasma was demonstrated for all spiked proteins without the application of front-end immunoaffinity depletion and fractionation. This significant improvement in detection sensitivity for low abundance proteins in complex matrices is expected to enhance a broad range of SRM-MS applications including targeted protein and metabolite validation. Molecular & Cellular Proteomics 10: 10.1074/ mcp.M000062-MCP201, 1-9, 2011.Although mass spectrometry (MS)-based proteomics is a promising high throughput technology for biomarker discovery and validation (1-5), only a handful of cancer biomarkers have been approved by the United States Food and Drug Administration for clinical use in the last decade (6, 7). Assuming that low abundance biomarkers do exist in the biofluids to be studied, the success of biomarker discovery efforts primarily depends on the sensitivity, accuracy, and robustness of the measurement technologies; the quality and size of patient cohorts and clinical samples and execution within the context of an overall difficult and expensive path to clinical application that encompasses discovery, verification, and validation stages (1, 5, 8 -10). A multiplexed assay platform increasingly considered for biomarker verification is selected reaction monitoring (SRM) 1 by tandem mass spectrometry using e.g. a triple quadrupole (QqQ) mass spectrometer to attain high throughput quantitative measurements of targeted proteins in complex matrices (1,11,12). SRM utilizes two stages of mass filtering by selecting a specific analyte ion of interest (precursor ion) in the first stage followed by a specific fragment ion derived from the precur...